RMC No. 122-2020 — Publishes the letter from the Food and Drug Administration regarding clarification on the List of VAT-Exempt Drugs Under Joint AO No. 2-2018 Digest | Full Text | FDA Letter

REPUBLIC OF THE PHILIPPINES

BUREAU OF INTERNAL REVENUE DEPARTMENT OF FINANCE

Q.3 NOV 2020

REVENUE MEMORANDUM CIRCULAR NO. 1&&- &D&0

SUBJECT: Publishing the Full Text of the Letter from the Food and Drug

Administration (FDA) of the Department of Health (DOH) with the Subject "Clarification on the List of VAT-Exempt Drugs Under Joint A0 No. 2-2018"

TO All Internal Revenue Officers and Others Concerned

concerned, attached is the letter dated August 7, 2020 from Jesusa Joyce N. Cirunay, Director For the information and guidance of all internal revenue officers, employees and others

products included in the lists initially provided for by the FDA that were circulated through IV for the Center for Drug Regulation and Research of the FDA, clarifying certain drug

RMC No. 62-2020 and RMC No. 101-2020, which is based on the International Non- Proprietary Name (INN) or generic name of the drug products which includes salt forms.

All concerned are hereby are enjoined to be guided accordingly and give this Circular as wide a publicity as possible.

cow

CAESAR R. DULAY

RECORDS MGT.DIVISION ENIYN C OAINTLRNALKEVENUC NOV 2 3 2020 9:40 AM. Ua Commissioner of Internal Revenue 037945

2: Ap